Background
==========

Schistosomiasis, an infectious disease caused by parasitic trematodes (schistosomes) dwelling in the host\'s mesenteric portal system, is a great public health problem in tropical and subtropical regions. The disease causes health and labor loss, and finally a significant reduction in socioeconomic benefits. Approximately 207 million people (more than 97% in Africa) are infected, and 779 million (85% in Africa) are at risk of being infected in 76 endemic countries worldwide, leading to the loss of about 4.5 million disability-adjusted life years (DALYs) \[[@B1]-[@B4]\]. Thus schistosomiasis control remains a challenge in endemic regions \[[@B4]-[@B7]\].

There are five schistosome species parasitizing in humans: *Schistosoma japonicum*, *S. mansoni*, *S. haematobium*, *S. mekongi*, and *S. intercalatum*. *S. japonicum*is transmitted by the amphibian snail *Oncomelania*and causes intestinal and hepatosplenic schistosomiasis in the People\'s Republic of China, Philippines, and Indonesia; *S. mansoni*, transmitted by *Biomphalaria*snails, causes intestinal and hepatic schistosomiasis in Africa, the Arabian peninsula, and South America; *S. haematobium*, transmitted by *Bulinus*snails, causes urinary schistosomiasis in Africa and the Arabian peninsula. *S. mekongi*and *S. intercalatum*are only of local importance \[[@B1]-[@B3],[@B8],[@B9]\].

In the mid-1980s, the WHO recommended schistosomiasis control strategies for humans by focusing on the large-scale population-based and repeated chemotherapy, which is still the key strategy today \[[@B10]\]. The chemotherapy for human schistosomiasis is to take antischistosomal drugs for prevention of morbidity in high-risk population (i.e. chemoprophylaxis by preventing the young schistosomes - schistosomula developing into adult egg-laying worms or killing them), and for treatment of patients by eliminating adult worms, whose eggs deposited in human tissue (e.g. liver and intestinal wall) and caused pathogenesis. For schistosomiasis treatment three drugs have been used, which differ in their effects on schistosome species: metrifonate (targeting *S. haematobium*), oxamniquine (targeting *S. mansoni*), and praziquantel (PZQ) (for all human species). Due to its broader spectrum, PZQ has finally become the first-line medicine. In recent years, however, the potential resistance problem of schistosomes to PZQ has come into concern, which may necessitate searching for alternatives \[[@B4],[@B11]-[@B15]\]. Among those are artemether (AM) and artesunate (AS), artemisinin derivatives (ARTs) with anti-schistosomal potential which was first described in the People\'s Republic of China in the early 1980s. ARTs were approved as schistosomiasis prevention drugs by the Chinese Ministry of Health in 1996 \[[@B16]\]. They are active against *S. japonicum*, *S. mansoni*and *S. haematobium*, mainly targeting the immature, pre-adult stage, the schistosomulum \[[@B17]-[@B21]\].

Only few publications, however, can be found with comprehensive and statistical assessments of the efficacy of these drugs controlling human schistosomiasis. To get a more detailed overview on the efficacy of PZQ and ARTs for human schistosomiasis treatment and prevention, we collected a large group of studies published in peer-reviewed journals, and conducted meta-analyses in categories to assess their antischistosomal efficacy comprehensively, including single drug monotherapy and drugs in combination against *S. japonicum*, *S. mansoni*, *S. haematobium*and *S. mekongi*.

Methods
=======

Search strategy and data sources
--------------------------------

We conducted a computer-aided search of the literature about anti-schistosomal efficacies assessments of PZQ, AM and AS used alone or in combination for human schistosomiasis. Source databases were the Cochrane Library (Issue 7, 2011), PubMed/Medline (1966 to July 2011), ISI Web of Science (1975 to July 2011), Chinese Bio-Medicine Literature Database (CBM, 1979 to July 2011) and China National Knowledge Infrastructure (CNKI, 1994 to July 2011). A review of European and American \"grey literature\" databases (NTIS, SIGLE) were also conducted. The terms and medical subject headings (MeSH) used in retrieving citations were \"schistosom\*\" (\* means the inclusion of all words with the preceding radical), \"praziquantel\", \"artemisinin\", \"artemether\", \"artesunate\", \"chemotherapy\". The retrieval formula was: schistosom\* AND (praziquantel OR artemether OR artesunate). The searches were performed mainly in Chinese and English with a limitation to human participants. One reviewer (LR) identified relevant studies by screening titles and abstracts; a manual search was performed systematically using the authors\' reference lists. The full-texts of potentially relevant studies were further evaluated by three reviewers (RL, HFD and YG).

Criteria of inclusion and exclusion
-----------------------------------

The inclusion criteria were: (i) independent studies assessing the antischistosomal efficacy of PZQ, AM and AS, administrated alone or in combination for human schistosomiasis treatment and prevention; (ii) the year of the study conducted or published was reported; (iii) the sample size was reported; (iv) the same drugs\' efficacy evaluation indicators between experimental populations and control populations, i.e. reporting parasitological outcome eggs-positive or eggs-negative by Kato-Katz thick stool smears technique and/or miracidia hatching tests for detecting eggs of *S. japonicum*, *S. mansoni*, and *S. mekongi*or urine filtration for detecting eggs of *S.haematobium*after approximately 3-4 weeks post-treatment, which was recommended as the standard method for schistosomiasis parasitological diagnosis by WHO in 1980 \[[@B10]\]; or reporting emergence or absence of acute schistosomiasis in the trials of assessing some drug\'s efficacy in controlling morbidity; (v) the studies were either randomized controlled trials (RCTs) or non-randomized control trials (nRCTs); (vi) with raw data which could be changed into relative risk (RR) and 95% CI RR and 95% CI were reported.

Exclusion criteria were: (i) study participants were not human; (ii) without control group; (iii) incomplete information; (iv) duplicate publications; (v) studies described only results without detailed background and method introduction; (vi) reviews. Figure [1](#F1){ref-type="fig"} summarizes the studies selection process.

![**Flow diagram showing the articles selection process for present meta-analyses of the efficacy of PZQ and ART (AM and AS) administrated alone or in combination for human schistosomiasis treatment or prevention**. Individual searches don\'t add up to 351 because some articles could be found simultaneously in multiple literature databases.](1756-3305-4-201-1){#F1}

Data extraction and methodological/quality assessment
-----------------------------------------------------

The following information was independently extracted by two reviewers (RL and YG) and was checked together, discrepancies were solved through discussion. The extracted information included: first author\'s name and year of publication, test sites (i.e. where trials were implemented), time (i.e. when trials were implemented), participants, *schistosoma*species, interventions, diagnostics methods, follow-up time, raw dichotomous data of efficacy assessment (NO. of positive/NO. of diagnosed), RRs and their 95% CIs, type of study design (RCT or nRCT), and intervention purposes (prevention or treatment).

The quality of included RCTs was assessed by examining whether there is randomization, blinding, and information about follow-up and dropouts/withdrawals of participants according to the guidance of the methodological quality assessment of RCTs in the *Cochrane Handbook for Systematic Reviews of Interventions 4.2.6*and the Jadad scoring criteria \[[@B22],[@B23]\]. The score for quality scale ranges from 0 to 5 points, the higher the score, the higher the quality of trial; and a trial with a Jadad score ≥3 has been considered to be of ample quality.

Diseases, interventions and outcomes
------------------------------------

Schistosomiasis japonica, schistosomiasis mansoni, schistosomiasis haematobia, and schistosomiasis mekongi were included in this meta-analysis. The participants included schoolchildren, villagers, schistosomiasis patients, fishermen, and people or soldiers participating in fighting against floods.

The participants of experimental groups took antischistosomal drugs such as PZQ, AM, or AS alone or in combination for treatment (to remove the adult worms from schistosomiasis patients by PZQ) or prevention (to control morbidity in high-risk population by ART or PZQ). Control groups took the same dose of placebo or PZQ (of the combination therapy trials) or nothing. The chemotherapeutic outcome evaluation was parasitological cure, which was defined as eggs-positive or eggs-negative, or emergence or absence of acute schistosomiasis symptoms.

Data synthesis and statistical analysis
---------------------------------------

Meta-analyses were conducted in categories of PZQ, AM, or AS alone and in combination, respectively. RRs based on dichotomous data were set as statistical indicators. Subgroup analyses were conducted according to different design types, *schistosoma*species, time of medication and dosages. The protection rates were calculated based on the summary RRs. All the statistical analysis work was performed using the statistical package ***Review Manager 4.3***software (Cochrane Collaboration, Oxford, UK) and ***Stata/SE 11***(*Stata*^®^Corporation, Texas, USA) for Egger\'s publication bias test by LR. The fixed-effects model was used to combine study-specific RRs, when there was no significant heterogeneity among studies. Otherwise, the random-effects model was used.

Publication bias and sensitivity analysis
-----------------------------------------

In order to examine the reliability and stability of our meta-analyses, publication bias was assessed by means of both funnel plot (qualitative) and Egger\'s publication bias test (quantitative). In addition, sensitivity analysis was performed by excluding some trials with different schistosome species (as the parasitological diagnosis method used for *S. haematobium*is different from that of other species) or with larger sample size.

Results
=======

Studies selected
----------------

Overall, 38 articles with 52 trials met the inclusion criteria and were finally used for this meta-analysis. Figure [1](#F1){ref-type="fig"} shows the studies\' selection process: 19 trials on PZQ\'s efficacy evaluation (9 RCTs and 7 nRCTs on treatment, 2 RCTs and 1 nRCT on prevention) \[[@B24]-[@B37]\]; 12 RCTs on AM\'s efficacy for prevention \[[@B38]-[@B49]\]; 16 RCTs on AS\'s efficacy (14 RCTs for prevention and 2 RCTs for treatment) \[[@B24],[@B30],[@B50]-[@B59]\], 6 RCTs out of Zhang et al.\'s study \[[@B55]\] of AS\'s efficacy in preventing *S. japonicum*infections reported the duplications of studies from Liu et al. \[[@B58]\], Yi et al. \[[@B56]\], Xu et al. \[[@B50],[@B51]\], and Liu et al. \[[@B57]\] and were excluded; one RCT on PZQ and AM in combination for treatment \[[@B60]\]; 3 RCTs on PZQ and AS in combination (2 RCTs for treatment and one for prevention) \[[@B24],[@B30],[@B61]\]. A number of 5 studies contained 2 or more independent trials \[[@B34],[@B35],[@B37],[@B38],[@B55]\]. Further 5 studies \[[@B62]-[@B66]\] were excluded for duplicate publication, and 3 studies for different design types \[[@B67]-[@B69]\].

Study characteristics and methodological quality
------------------------------------------------

Studies were conducted in areas that are endemic for human schistosomiasis, including Nigeria, Burkina Faso, Niger, KwaZulu/Natal of South Africa, Côte d\'Ivoire, Gabon, Philippines, Tanzania, Brazil, and China (see Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). PZQ dosages applied ranged from a single oral dose of 30-60 mg/kg or divided (2-3) dosages in RCTs-designed studies, and only one trial reported about participants who had received a single oral dose of PZQ at 20 mg/kg \[[@B35]\]. For nRCTs about PZQ\'s efficacy, there were several types of drug administration i.e. a single oral dose of 40 mg/kg or 60 mg/kg, multiple (2-3) oral doses of the same concentrations, two doses of 40 mg/kg, and two doses of 30 mg/kg added by another dose of 40 mg/kg. The dosage of AM given was 6 mg/kg/day, ranging from 2 doses to 13 doses over about 15-day intervals, 3-week intervals, or one-month interval, for preventing schistosomiasis morbidity. AS was applied by two medication types, 4 mg/kg/day over 3 consecutive days for treatment, or 3-14 doses of 6 mg/kg/day over 1- or 2-weeks intervals for prevention. For PZQ and AM in combination participants of the experimental group received a single oral dose of 60 mg/kg PZQ and 6 mg/kg/day AM \[[@B60]\]; for PZQ and AS in combination for treating schistosomiasis haematobia, participants received a single oral dose of 40 mg/kg PZQ and a dose of 4 mg/kg/day AS \[[@B24],[@B29]\]. Participants in the control groups received just a single oral dose of 40 or 60 mg/kg PZQ and AM placebo or AS placebo. In another study with PZQ and AS in combination to treat schistosomiasis japonica by soldiers participating in fighting against floods, participants of the experimental group received 1200 mg PZQ once divided into two doses and AS 300 mg once for every 7 days, participants in the control group received nothing \[[@B61]\]. The follow-up time post-treatment differed from studies ranging from 2 weeks to more than 2 years, most of which ranged from 4 weeks to half a year. Table [1](#T1){ref-type="table"} summarizes the Jadad scores of the included RCTs. Among the 29 RCT-designed studies, only 5 studies \[[@B29],[@B40],[@B41],[@B43],[@B51]\] have described the randomization method; one study \[[@B37]\] did not include blinded allocation or outcome measurements, and 11 studies \[[@B24],[@B38],[@B43],[@B49],[@B51]-[@B55],[@B57],[@B58]\] had no description of withdrawals or dropouts. Thus 28 of the included RCTs were rated as providing good methodological quality based on a Jadad score of 3-5, and only one study \[[@B37]\] had a Jadad score of 2. The nRCTs without quality assessment were analyzed separately from the RCTs.

###### 

Assessment of methodological quality of the included RCTs by Jadad scoring criteria\*

  Trial                  Randomized†   Double-blinded§   A description of withdrawals or dropouts   Jadad score
  ---------------------- ------------- ----------------- ------------------------------------------ -------------
  Inyang-Etoh PC, 2009   1             2                 0                                          3
  Borrmann S, 2001       2             2                 1                                          5
  Santos AT, 1979        1             2                 1                                          4
  McMahon JE, 1979       1             1                 1                                          3
  Katz N, 1979           1             2                 1                                          4
  Liu ZG, 1997           1             0                 1                                          2
  Song Y, 2006           1             2                 0                                          3
  Li YS, 2005            1             2                 1                                          4
  N\'Goran EK, 2003      2             2                 1                                          5
  Utzinger J, 2000       2             2                 1                                          5
  Tian ZY, 1999          2             2                 0                                          4
  Huang AS, 1999         1             2                 1                                          4
  Song Y, 1998           1             2                 1                                          4
  Xu MS, 1997            1             2                 1                                          4
  Tian ZY, 1997          1             2                 1                                          4
  Wang JL, 1997          1             2                 1                                          4
  Xiao SH, 1996          1             2                 0                                          3
  Xiao SH, 1995          1             2                 1                                          4
  Xu MS, 2001            1             2                 0                                          3
  Cui JF, 2001           1             2                 0                                          3
  Sun MX, 2000           1             2                 0                                          3
  Zhang SJ, 2000         1             2                 0                                          3
  Yi ZH, 2000            1             2                 1                                          4
  Liu HY, 1999           1             2                 0                                          3
  Xu MS, 1998            2             2                 0                                          4
  Liu ZD, 1996           1             2                 0                                          3
  Xu MS, 1996            1             2                 1                                          4
  Wu LJ, 1995            1             2                 1                                          4
  Hou XY, 2008           1             2                 1                                          4

\* Range 0\~5 (the higher the Jadad score is, the higher the quality of study is).

† Represents generation of allocation sequence.

§ Represents allocation concealment.

Meta-analysis
-------------

Compared to results using a placebo, a single dose of 30-60 mg/kg PZQ provided a protection rate of 76% (95% CI: 67%-83%) for treatment of schistosomiasis japonica, which was higher as point estimation than its protection rate against schistosomiasis haematobia \[72% (95% CI: 65%-78%)\] or schistosomiasis mansoni \[70% (95% CI: 25%-88%)\]. But, the differences of protection rates among the three species are of no statistical significance with regard to their 95% CIs, and their overall pooled protection rate is 73% (95% CI: 67%-78%); meanwhile, the increasing dosage within 30-60 mg/kg gives no significant improvement in efficacy. Compared to this, 20 mg/kg PZQ seems to be less effective resulting in a protection rate of just 16% (95% CI: -81%-61%). For PZQ\'s efficacy during nRCTs, dosages of 60-100 mg/kg (i.e. 60/(40 × 2 doses)/(30 × 2 doses + 40) mg/kg) provide better efficacies than a single dose at 40 mg/kg, their protection rates were 91% (95% CI: 88%-92%) vs. 52% (95% CI: 49%-55%), respectively. In addition, several doses of PZQ at 40 mg/kg of both two RCTs and one nRCT produced great effects on preventing schistosomiasis morbidity, their protection rates were 98% (95% CI: 93%-99%) and 100%, respectively. Multiple (6-7) doses of 6 mg/kg AM applied in 1-month intervals resulted in protection rates of 24% (95% CI: 8%-37%) with respect to preventing *S. japonicum*infections, which increased to 50% (95% CI: 29%-65%) when the time interval was shortened to 3-week intervals; 4-7 doses of 6 mg/kg AM applied in 15-day intervals led to protection rates of 65% (95% CI: 50%-76%) in preventing *S. japonicum*infections, which increased significantly to 90% (95% CI: 79%-95%) when the dosages were increased to 8-13 doses. In addition, 2-3 doses of 6 mg/kg AM with 15-day intervals produced great effects on preventing against *S. japonicum*infection in persons of short term exposure, who e.g. participated in fighting against floods, here, the protection rate was 91% (95% CI: 76%-97%). 3 doses of 6 mg/kg AS given during 1-week intervals used to prevent *S. japonicum*infection resulted in protection rates of 89% (95% CI: 55%-97%), which rose to 97% (95% CI: 88%-99%) when the dosages increased to 8 doses; 3-5 doses of 6 mg/kg AS applied in 2-week intervals used to prevent *S. japonicum*infection led to a protection rate of 71% (95% CI: 48%-84%), which rose significantly to 95% (95% CI: 91%-97%) when the dosages increased to 8-14 applications. Two studies showed no significant effects of AS treatments compared to a placebo, with a protection rate of 45% (95% CI: -78%-83%) which spanned across zero. PZQ and ART (AM or AS) in combination used for schistosomiasis treatment resulted in a better efficacy than PZQ treatment alone, with a pooled RR of 0.61 (95% CI: 0.39-0.96) and a protection rate of 39% (95% CI: 4%-61%), which was converted to 84% (95% CI: 64%-91%) after the control PZQ was transformed into placebo based on the RCTs\' result of PZQ at 30-60 mg/kg for treatment. PZQ and AS in combination had a great effect on prevention against *S. japonicum*infection with a protection rate of 96% (95% CI: 78%-99%). All of these results are summarized in detail in Figure [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"} and Table [2](#T2){ref-type="table"}.

![**Forest plots showing the efficacy of PZQ (30-60 mg/kg) for schistosomiasis treatment (RCTs)**. n/N = number examined as positive outcome (or not cured) over number of participants who were examined. Sub-groups with trials with patients infected by different *Schistosoma*species (01: *S. haematobium*, 02: *S. mansoni*, and 03: *S. japonicum*) were separately combined. The *P*value of each test for heterogeneity was ≥0.05, thus the fixed-effect model was used to combine trial-specific RRs of each sub-group and the total pooled RR, and its 95% CI were calculated by combing all sub-groups. No statistically significant difference among pooled RRs of sub-groups about different species was observed.](1756-3305-4-201-2){#F2}

![**Forest plots showing the efficacy of AM using 6 mg/kg for preventing schistosome infection (RCTs)**. The trials were stratified into sub-groups based on dosages and *Schistosoma*species. (01) 4-7 doses by 15-day intervals for preventing *S. japonicum*infection (pooled RR was synthesized by the fixed-effect model); (02) 2-3 doses by 15-day intervals for preventing *S. japonicum*infection of short term exposure; (03) 8-13 doses by 15-day intervals for preventing *S. japonicum*infection (pooled RR was synthesized by random-effect model); (04) 6-7 doses by 3-week intervals for preventing *S. mansoni*infection; (05) 6-7 doses by 1-month intervals for preventing schistosome infection - *S. haematobium*and *S. japonicum*(pooled RR was synthesized by the fixed-effect model).](1756-3305-4-201-3){#F3}

![**Forest plots showing the efficacy of AS using 6 mg/kg for preventing *S. japonicum*infection (RCTs)**. The trials were stratified into sub-groups based on different dosages and time intervals between every two adjacent doses. (01) 8 doses by 1-week intervals; (02) 3 doses by 1-week intervals; (03) 8-14 doses by 2-week intervals; (04) 3-5 doses by 2-week intervals. The *P*values of test for heterogeneity of subgroups 01, 03 and 04 were \>0.05 each, thus the pooled RRs were synthesized by the fixed-effect model.](1756-3305-4-201-4){#F4}

![**Forest plots showing the efficacy of PZQ and ARTs (AM or AS) in combination for schistosomiasis treatment**. (01) PZQ and AS in combination for treating against *S. haematobium*or *S. japonicum*; (02) PZQ and AM in combination for treating against *S. japonicum*. The pooled RR of 0.61 (95% CI: 0.39-0.96) was determined by combing the two subgroups as the *P*value of overall heterogeneity test was 0.62.](1756-3305-4-201-5){#F5}

###### 

Estimates of summary RRs and protection rates of the antischistosomal drugs\' efficacy

  Studies included                                                                                              Trials (n)\*   **Participants (N**~**1**~**/N**~**2**~**)**^**Δ**^   **Pooled RRs (95% CI)**^**▲**^   Protection rates % (95% CI)   Heterogeneity test, *P*values
  ------------------------------------------------------------------------------------------------------------- -------------- ----------------------------------------------------- -------------------------------- ----------------------------- -------------------------------
  **PZQ for treatment**                                                                                         **16**         **4108/5331§**                                        \-                               \-                            \-
   • RCT designed (20 mg/kg) against *S. mansoni*                                                               1              4/2                                                   0.84 (0.39, 1.81)                16 (-81, 61)                  \-
   • RCT designed (30-60 mg/kg)                                                                                 8              348/220                                               0.27 (0.22, 0.33)                73 (67, 78)                   0.88
    •*S. haematobium*                                                                                           5              220/164                                               0.28 (0.22, 0.35)                72 (65, 78)                   0.70
    •*S. mansoni*                                                                                               2              12/13                                                 0.30 (0.12, 0.75)                70 (25, 88)                   0.85
    •*S. japonicum*                                                                                             1              116/43                                                0.24 (0.17, 0.33)                76 (67, 83)                   \-
   • nRCT designed (40 mg/kg)                                                                                   3              2375/2847                                             0.48 (0.45, 0.51)                52 (49, 55)                   \<0.01
   • nRCT designed (60/(40 × 2)/(30 × 2 + 40) mg/kg)                                                            4              1381/2262                                             0.09 (0.08, 0.12)                91 (88, 92)                   0.17
  **PZQ for prevention against *S. japonicum***                                                                 **3**          **2405/121**                                          \-                               \-                            \-
   • RCT designed                                                                                               2              155/61§                                               0.02 (0.01, 0.07)                98 (93, 99)                   0.15
   • nRCT designed                                                                                              1              2250/60                                               0.00 (0.00, 0.00)                100                           \-
  **AM for prevention (6 mg/kg) (RCTs)**                                                                        **13**         **4030/3771§**                                        \-                               \-                            \-
   • 2-3 doses by 15-day interval against *S. japonicum*by short term exposure during fighting against floods   1              202/212                                               0.09 (0.03, 0.24)                91 (76, 97)                   \-
   • 4-7 doses by 15-day interval against *S. japonicum*                                                        3              713/706                                               0.35 (0.24, 0.50)                65 (50, 76)                   0.65
   • 8-13 doses by 15-day interval against *S. japonicum*                                                       6              2429/2563                                             0.10 (0.05, 0.21)                90 (79, 95)                   \<0.01
   • 6-7 doses by 3-week interval against *S. mansoni*                                                          1              128/140                                               0.50 (0.35, 0.71)                50 (29, 65)                   \-
   • 6-7 doses by 1-month interval against *S. haematobium*and *S. japonicum*                                   2              558/737                                               0.76 (0.63, 0.92)                24 (8, 37)                    0.88
  **AS (6 mg/kg) for preventing *S. japonicum*infection (RCTs)**                                                **14**         **5012/5241**                                         \-                               \-                            \-
   • 3 doses by 1-week interval                                                                                 1              168/200                                               0.11 (0.03, 0.45)                89 (55, 97)                   \-
   • 8 doses by 1-week interval                                                                                 4              813/720                                               0.03 (0.01, 0.12)                97 (88, 99)                   0.89
   • 3-5 doses by 2-week interval                                                                               4              714/768                                               0.29 (0.16, 0.52)                71 (48, 84)                   0.20
   • 8-14 doses by 2-week interval                                                                              5              3317/3553                                             0.05 (0.03, 0.09)                95 (91, 97)                   0.93
  **AS (4 mg/kg × 3 doses) for treating S. haematobia (RCTs)**                                                  **2**          **132/74**                                            **0.55 (0.17, 1.78)**            **45 (-78, 83)**              **\<0.01**
  **PZQ + AM/AS for treatment (RCTs)**                                                                          **4**          **227/234**                                           **0.61 (0.39, 0.96)**            **84 (64, 91) †**             **0.62**
   • PZQ + AM against *S. japonicum*                                                                            1              95/101                                                0.53 (0.10, 2.84)                86 (6, 98) †                  \-
   • PZQ + AS against *S. haematobium*                                                                          2              132/133                                               0.62 (0.38, 0.99)                83 (62, 92) †                 0.33
  PZQ + AS for prevention against *S. japonicum*(nRCT)                                                          1              1362/112                                              0.04 (0.01, 0.22)                96 (78, 99)                   \-

\* There are 39 studies with53 trials included as some of the studies have multiple drugs trials.

Δ N~1~/N~2~= the number of participants in test group/the number of participants in control group.

▲ Pooled RRs (95% CI) are presented which were calculated by fixed-effects model when *P*value ≥0.05 of heterogeneity test, and by random-effects model if not.

† Their average protection rates and 95% CI were calculated when the drugs given to the controls were transformed into placebo (based on the RCTs results of PZQ 30-60 mg/kg for treatment).

§ The sum of participants in subgroups doesn\'t equal the true total because some studies \[[@B35],[@B39],[@B64]\] have the same control participants.

Publication bias and sensitivity analysis
-----------------------------------------

Funnel plots and Egger\'s test results of publication bias estimation of each subgroup based on study-specific RRs showed that in most subgroups the included trials are almost evenly distributed around the vertical axis of pooled RR and within the 95% CI of pooled log RR (Figures [6](#F6){ref-type="fig"},[7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"} and [9](#F9){ref-type="fig"}). This indicated that no evidence of a publication bias exists, except for the subgroup RCTs-designed of 8-13 doses of 6 mg/kg AM during 15 day-intervals used for prevention against *S. japonicum*infection. The *P*value of Egger\'s test was 0.01, which indicated that a publication bias may exist. In addition, sensitivity analyses indicated there were no significant changes in the results of RRs\' estimation and their 95% CIs between the restricted data sets and their combined overall values in each subgroup (Table [3](#T3){ref-type="table"}). Thus the results of our meta-analyses are stable and credible.

![**Funnel plot and Egger\'s publication bias test for RCTs of PZQ\'s efficacy on schistosomiasis treatment**. The pooled log-RR for these trials is shown with a dashed vertical line, and the dashed slash lines distributed in both sides are the cutoff values of 95% CI of pooled log RR. The Egger\'s publication bias test showed that no publication bias exists (*P*= 0.96).](1756-3305-4-201-6){#F6}

![**Funnel plot and Egger\'s publication bias test for RCTs (2-7 doses by 15-day intervals) of AM\'s efficacy on preventing *S. japonicum*infection**. There is one point (representing one trial) outside the cutoff values of 95% CI of pooled log RR. The Egger\'s publication bias test showed that no publication bias exists (*P*= 0.53).](1756-3305-4-201-7){#F7}

![**Funnel plot and Egger\'s publication bias test for RCTs (8-13 doses in 15-day intervals) of AM\'s efficacy on preventing *S. japonicum*infection**. There are two points (represented two trials) distributing outside the cutoff values of 95% CI of pooled log RR. The Egger\'s publication bias test showed that a publication bias may exist (*P*= 0.01).](1756-3305-4-201-8){#F8}

![**Funnel plot and Egger\'s publication bias test for RCTs of AS\'s efficacy on preventing *S. japonicum*infection**. The Egger\'s publication bias test showed that no publication bias exists (*P*= 0.18).](1756-3305-4-201-9){#F9}

###### 

Sensitivity analysis of the efficacy of drugs targeting different species of schistosome (RCTs only)

  Study                                                       Method\*   No. of Trials   **Participants (N**~**1**~**/N**~**2**~**)**   Pooled RRs (95%CI)      Heterogeneity Test (*P*)
  ----------------------------------------------------------- ---------- --------------- ---------------------------------------------- ----------------------- --------------------------
                                                              **A**      **8**           **348/220**                                    **0.27 (0.22, 0.33)**   **0.88**
  PZQ (RCTs) for treatment                                    B          7               232/177                                        0.28 (0.22, 0.35)       0.90
                                                              C          6               336/207                                        0.27 (0.22, 0.32)       0.70
                                                              D          5               220/164                                        0.28 (0.22, 0.35)       0.70
  AM for prevention (8-13 doses by 15-day interval)           **A**      **6**           **2429/2563**                                  **0.10 (0.05, 0.21)**   **\<0.01**
                                                              E          5               1996/2111                                      0.12 (0.06, 0.24)       \<0.01
  AS (6 mg/kg) 8 doses by 1-week interval for preventing      **A**      **4**           **813/720**                                    **0.03 (0.01, 0.12)**   **0.89**
                                                              F          2               572/502                                        0.02 (0.00, 0.14)       0.73
  AS (6 mg/kg) 8-14 doses by 2-week interval for preventing   **A**      **5**           **3317/3553**                                  **0.05 (0.03, 0.09)**   **0.93**
                                                              G          4               879/893                                        0.04 (0.01, 0.14)       0.83
  AS (6 mg/kg) 3-5 doses by 2-week interval for preventing    **A**      **4**           **714/768**                                    **0.29 (0.16, 0.52)**   **0.20**
                                                              H          3               334/368                                        0.39 (0.20, 0.76)       0.39

\*A: all trials were included in each subgroup, respectively.

B: one trial \[[@B34]\] with *S. japonicum*species was excluded.

C: two trials \[[@B36]\] with *S. mansoni*species were excluded.

D: three trials \[[@B34],[@B36]\] were excluded, the remaining with *S. haematoium.*

E: one trial \[[@B47]\] in which there was zero person positive in the treatment group was excluded.

F: two trials from the same study \[[@B56]\] were excluded.

G: one trial \[[@B53]\] with the largest sample size was excluded.

H: one trial \[[@B52]\] with the largest sample size was excluded.

Adverse effects
---------------

Adverse effects were reported for people who had taken PZQ for treatment or prevention against schistosomiasis. Among those were dizziness, stomach discomfort or stomach ache, headache, nausea, debility, muscular and joint soreness, and diarrhoea, which disappeared shortly after drug withdrawal \[[@B70],[@B71]\]. In the trials of Tian et al. \[[@B42]\], Song et al. \[[@B38],[@B45]\], Xu et al. \[[@B46]\], Wang et al. \[[@B47]\] and Xiao et al. \[[@B48],[@B49]\] about assessing the efficacy of AM in preventing against *S. japonicum*in the regions of Anhui, Hunan, Jiangxi and Yunnan provinces, only a few of total 4, 754 participants aged from 5 to 60 years old experienced symptoms of mild and transient dizziness, headache, and abdominal pain symptoms with good tolerance and less severe adverse effects \[[@B72],[@B73]\]. AS was also reported being well tolerable. Only about 1% of the participants reported about mild abdominal pain, dizziness, headache and diarrhoea, or slight fever \[[@B59]\].

Discussion
==========

PZQ was synthesized by Bayer and Merck in Germany in 1972 \[[@B74]\], and introduced for clinical use in the People\'s Republic of China since 1978 \[[@B74],[@B75]\]. Today, PZQ is the most frequently used drug for schistosomiasis treatment in endemic areas, and regularly used also in large scale programmes \[[@B76]\]. PZQ exhibits stage-specific functions in killing adult worms \[[@B73],[@B77],[@B78]\]. Our meta-analysis showed that a single oral dose of 30-60 mg/kg PZQ or 40/60 mg/kg divided in two doses during RCTs resulted in protection rates of 73% (95% CI: 67%-78%) for treating schistosomiasis. No significant differences were observed among the species *S. haematobium*, *S. japonicum*and *S. mansoni*, but the protective efficacy decreases significantly to 16% (95% CI: -81%-61%) when the PZQ dosage decreased to a single dose of 20 mg/kg. Similarly, 60-100 mg/kg PZQ (i.e. 60 mg/kg as single or double treatment, two doses of 40 mg/kg, or two doses of 30 mg/kg adding a single dose of 40 mg/kg) during nRCTs revealed protection rates of 91% (95% CI: 88%-92%). The protective effect declined significantly to 52% (95% CI: 49%-55%) when the dosage was reduced to a single dose of 40 mg/kg. Thus it can be concluded that multiple doses of 40/60 mg/kg PZQ provide an enhanced efficacy in treating schistosomiasis compared to a single dose. Additionally, when PZQ was applied during the 3^rd^-4^th^week after the first exposure of a patient to infected water harboring schistosome cercariae, is turned out to be also effective in preventing acute schistosomiasis morbidity with a protections rate of 98% (95% CI: 93%-99%) in two RCTs, and 100% of one nRCT \[[@B36],[@B62]\]. Temporal observations and long-term follow-up investigations about adverse effects showed that PZQ had low toxicity, mild adverse symptoms, no malformation effects, and no sequel. The incidence rates of heavy side-effects were between 0.47% and 1.54% \[[@B79]\]. Thus PZQ has been a safe and effective antischistosomal drug with a broad applicability for all species of schistosome \[[@B35],[@B80]\].

One key issue of chemotherapy for human schistosomiasis treatment is the concern of investigators and clinicians for the emergence of PZQ resistance \[[@B81]-[@B83]\]. To date, there is no convincing clinical evidence for schistosome resistance to PZQ used for human schistosomiasis treatment, although worrying low-cure rates have been reported in some studies \[[@B84]-[@B93]\]. Our meta-analysis covering a publication period from 1979 to 2009 indicated that PZQ is still effective for *S. haematobium*, *S. mansoni*and *S. japonicum*with negligible variations. We conclude that there is no reason to be worried about the spreading of extensive and serious PZQ resistance, which as King et al. mentioned in 2000 \"\... will likely take 10 or more years to emerge\" \[[@B94]\]. However, one should not lose sight of first evidence for reports indicating the existence of PZQ-tolerable schistosomes which have emerged locally in some African areas \[[@B90]\]. The observed variations between the results of RCTs and nRCTs are explained by the slack design of these nRCTs\'. However, dose response trends are the same in RCTs and nRCTs, i.e. larger dosage or more treatment time points increase PZQ\'s efficacy.

AM and AS, the derivatives of artemisinin (ART), which was first extracted from the sweet wormwood herb *Artemisia annua*by Chinese chemist Youyou Tu and her team in 1970s, were at first used for the treatment of malaria (<http://www.laskerfoundation.org/awards/2011_c_description.htm>); their potential against *S. japonicum*was first reported in the 1980s \[[@B95],[@B96]\], just some years after the discovery of the antischistosomal properties of artemisinin \[[@B97]\]. ARTs were approved as antischistosomal drugs by the Chinese Ministry of Health in 1990s \[[@B74]\]. AM and AS have similar functions and kill larval worms (schistosomula) of different schistosome species. Thus they have been used as chemoprophylactic drugs against schistosomes and could induce resistance to reinfection \[[@B73],[@B74],[@B98]\]. Our meta-analyses suggest that shortening application intervals could improve their preventive potential. Best efficacies were obtained with 8 or more doses of 6 mg/kg AM applied with 15-day intervals (\[90% (95% CI: 79%-95%\]), or with 6 mg/kg AS applied with 1-week intervals (97% \[95% CI: 88%-99%\]). AS, however, showed poor performance with respect to schistosomiasis treatment \[[@B24],[@B29]\] (Table [2](#T2){ref-type="table"}). Thus AM and AS seem to be suitable as chemoprophylactic drugs for preventing schistosomiasis morbidity, but they seem not to be competent for treating schistosomiasis. In clinical studies using AM or AS to prevent schistosomiasis incidence rates of less than 1% side-effects were reported \[[@B71],[@B74],[@B99],[@B100]\]. Up to now, there haven\'t been any reports about drug resistance of schistosomes to these two drugs \[[@B101]-[@B103]\] besides one exception. Hua et al \[[@B104]\] reported recently that the sensitivity of artesunate against *S. japonicum*has decreased after 10 years of use in China. The study reported about protection rates obtained after the application of 4 doses of 6 mg/kg AS given over 3-day intervals between the 1^st^and the 2^nd^dose and the 3^rd^and the 4^th^dose, A 11-day interval occurred between the 2^nd^and the 3^rd^treatment. Surprisingly, the protection rate during that time period was 74.8%, but it fell to 13.5% when the AS application was changed to 4 doses of 6 mg/kg AS given in 1-week intervals. This unexpected result is difficult to reconcile with similar study reports, and because of its not-perfect study design and contradictory statements between study design and drug administration of participants, why it was not included in our meta-analysis. Although the authors concluded that they identified potential artemisinin-derivate-resistance in *S. japonicum*, we believe, that more rigorous research is needed to confirm this finding \[[@B105]\].

Our meta-analysis showed that PZQ and AS in combination provided similar preventive efficacy than those obtained by AM or AS administrated as single drugs (approximately 90%-97%). In conclusion, AM or AS alone have the capacity as prophylactic drugs for schistosomiasis prevention. PZQ and AM or AS in combination for treatment resulted in higher protection rates (84% \[95% CI: 64%-91%\]) than PZQ alone (73% \[95% CI: 67%-78%\]), respectively. Thus PZQ-ARTs combinations are useful for schistosomiasis patients repeatedly exposed to infected water. It\'s well known that ARTs are used in large-scale programmes for malaria treatment (mostly epidemic in Africa). However, ARTs-resistant malarial parasites have been identified and confirmed in some areas \[[@B106]-[@B108]\]. Thus using ARTs for schistosomiasis control is not advisable in areas where schistosomiasis and malaria are co-endemic.

One limitation of this meta-analysis is that the diagnostic approaches used to determine parasites were different among the included trials. There were differences between Kato-Katz technique and urine filtration, the number of specimens, and the number of examinations between trials. The former cannot be changed because it is determined by the two kinds of different clinical pathogenesis. The latter can be improved through using a standardized, quality-controlled diagnostic criterion within and between trials. As discussed by Bergquist et al. \[[@B109]\] and Danso-Appiah et al. \[[@B110]\], different diagnostic methods own different sensitivity and specificity, and the same method also owns different sensitivity and specificity for different infection levels and different numbers of specimens, which were called the diagnostic dilemmas. In the current meta-analyses, we tried to stratify the included trials based on their diagnostic approaches and the numbers of specimens and examinations. However, we were restricted doing this since many of the included trials didn\'t report about the numbers of specimens and examinations for each participant. Thus a unified study design is urgently needed to make the study outcomes more comparable.

The results of the RCTs dealing with PZQ or ART efficacies (using 40 mg/kg for treatment; 8-13 doses of 6 mg/kg AM with 15-day intervals for preventing, and AS for treatment) have *P*values \<0.05, which indicates that the studies included in these three subgroups were heterogeneous. We presume that some factors such as e.g. regional variances, participants\' differences, or drug dosage differences among these studies, may have contributed to this heterogeneity \[[@B111]\]. RCTs are preferable to be conducted when assessing drug efficacies in order to exclude the influence of such variable factors. Different species of schistosome were thought to have different susceptibility to these drugs, and we stratified the included trials and performed subgroup meta-analysis. Interestingly, the results provided no hint in this direction when different species were used in RCTs using PZQ (30-60 mg/kg for schistosomiasis treatment), AM (6-7 doses of using 6 mg/kg in 1-month intervals for preventing schistosomiasis), and PZQ + ART combinatory schistosomiasis treatment, in which the three schistosome species *S. haematobium*, *S. japonicum*and *S. mansoni*were studied (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [5](#F5){ref-type="fig"}). We conclude that these drugs may be equally effective against these schistosome species, which we confirmed also by the results of sensitivity analysis (Table [3](#T3){ref-type="table"}).

Publication bias is usually cited as a reason for the lack of validity in meta-analyses \[[@B112]\]. Publication bias can occur when studies that found no significant effect of antischistosomal drugs in schistosomiasis control are less likely submitted and accepted for publication than those with a positive result. The funnel plots of the included trials showed no evidence for publication bias except the subgroup of 8-13 doses of at 6 mg/kg AM given with 15-day intervals for preventing schistosomiasis. Two points (represented two trials) were outside the cutoff line, and the *P*value of Egger\'s publication bias test was 0.01, implying the existence of publication bias.

Additionally, we had found two Cochrane reviews discussing drugs for human schistosomiasis treatment \[[@B113],[@B114]\], one review examined PZQ, metrifonate and artemisinin derivatives used alone or in combination for treating urinary schistosomiasis, and the other assessed the effects of oxamniquine and praziquantel on treatment against *S. mansoni*. Thus our meta-analysis represents a good complementary data set adding to the results obtained in these studies.

Conclusions
===========

Facing the fact that an integrated strategy, which emphasizes health education, access to clean water and adequate sanitation, mechanization of agriculture, and fencing of water buffaloes (mainly for schistosomiasis japonica endemic areas), along with mass chemotherapy for both human and livestock, have been suggested to be carried out in parallel to control the infection sources and to stop schistosome transmission \[[@B115]-[@B118]\], we strived to conduct this meta-analysis hoping to provide a scientific basis for monitoring and selecting antischistosomal drugs efficiently, which is a crucial job for the schistosomiasis integrated control programme. With respect to the results obtained in our meta-analyses, we recommend to use multiple doses of AM or AS at 6 mg/kg given in 1- or 2-week intervals for prevention against schistosome infection during exposure to infected water. PZQ remains effective in schistosomiasis treatment, and multiple doses of PZQ at 30-60 mg/kg can improve its efficacy. PZQ and AM or AS administrated in combination are more effective than single drug PZQ therapy, which maybe especially suitable for the treatment of patients, who are repeatedly exposed to infected water.
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###### Additional file 1

**Table S1 Summary of the characteristics of the included trials in our meta-analyses evaluating antischistosomal drugs (PZQ, AM and AS), used alone or in combination, for human schistosomiasis treatment or prevention**. This table describes the extracted characteristics of the included studies: Author, Year; Test sites; Time; Participants; Species; Interventions; Diagnostic approach; Follow-up time; Treated (n/N); Controlled (n/N); Relative Risk; (95%CI); Design Type; Usage.
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